Memantine in vascular dementia

International Psychogeriatrics

Volumn 15, Issue SUPPL. 1, 2003, Pages 207-213

  Möbius, Hans Jörg ^a   Stöffler, Albrecht ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

ADAS cog; Memantine; Randomized controlled trial (RCT); Vascular dementia (VaD)

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO;

AGED; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; BRAIN; DEMENTIA, VASCULAR; DOPAMINE AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MEMANTINE; NEUROPSYCHOLOGICAL TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 18344411377     PISSN: 10416102     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1041610203009219     Document Type: Conference Paper

References (13)

1. Barnes, C. A., Danysz, W., & Parsons, C. G. (1996). Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. European Journal of Neuroscience, 8, 565-571.
2. Danysz, W., Parsons, C. G., Mòbius, H. J., Stöffler, A., & Quack, G. (2000). Neuroprotection and symptomatological action of memantine relevant for Alzheimer's disease-A unified hypothesis on the mechanism of action. Neurotoxicology Research, 2, 85-98.
3. Erkinjuntti, T., Inzitari, D., Pantoni, L., Wallin, A., Scheltens, P., et al. (2000). Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission, 59(Suppl.), 23-30.
4. Gauthier, S., & Ferris, S. (2001). Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease. International Journal of Clinical Practice, 120, 29-39.
5. Goertelmeyer, R., & Erbler, H. (1992). Memantine in the treatment of mild to moderate dementia syndrome: A double-blind placebo-controlled study. Arzneimittel-Forschung/Drug Research, 42, 904-913.
6. Inzitari, D., Erkinjuntti, T., Wallin, A., Del Ser, T., Romanelli, M., et al. (2000). Subcortical vascular dementia as a specific target for clinical trials. Annals of the New York Academy of Sciences, 903, 510-521.
7. Móbius, H. J. (1999). Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Disease and Associated Disorders, 13(Suppl. 3), S172-S178.
8. Orgogozo, J. M., Rigaud, A. S., Stöffler, A., Möbius, H. J., & Forette, F. (2002). Efficacy and safety of memantine in patients with mild to moderate vascular dementia; a randomized, placebo-controlled trial (MMM300). Stroke, 33, 1834-1839.
9. Reisberg, B., Doody, R., Stòffler, A., Schmitt, F., Ferris, S., et al. (2003). Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine, 348, 1333-1341.
10. Wilcock, G., Stöffler, A., & Móbius, H. J. (2002). A double-blind, placebo-controlled multicenter study of memantine in mild to moderate vascular dementia (the MMM500 trial). International Clinical Psychopharmacology, 17, 297-305.
11. Wilcock, G., Stoeffler, A., Sahin, K., & Moebius, H. J. (2000). Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment: A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. European Neuropsychopharmacology, 10(Suppl. 3), S360.
12. Winblad, B., & Poritis, N. (1999). Memantine in severe dementia: Results of the M-best study (benefit and efficacy in severely demented patients during treatment with memantine). International Journal of Geriatric Psychiatry, 14, 135-146.
13. Zajaczkowski, W., Quack, G., & Danysz, W. (1996). Infusion of (+)-MK-801 and memantine: Contrasting effects on radial maze learning in rats with entorhinal cortex lesion. European Journal of Pharmacology, 296, 239-246.